Valeant Pharmaceuticals International Inc. (NYSE:VRX)‘s stock had its “hold” rating reaffirmed by Canaccord Genuity in a research note issued on Wednesday. They currently have a $17.00 price objective on the specialty pharmaceutical company’s stock, down from their previous price objective of $33.00. Canaccord Genuity’s target price indicates a potential upside of 1.07% from the stock’s previous close.

Several other research analysts have also recently issued reports on the company. JPMorgan Chase & Co. reissued a “neutral” rating on shares of Valeant Pharmaceuticals International in a research report on Tuesday, October 25th. Mizuho reaffirmed an “underperform” rating and set a $11.00 price objective on shares of Valeant Pharmaceuticals International in a research report on Tuesday, July 26th. RBC Capital Markets reaffirmed a “sector perform” rating and set a $33.00 price objective on shares of Valeant Pharmaceuticals International in a research report on Tuesday, July 19th. Guggenheim reaffirmed a “buy” rating and set a $55.00 price objective on shares of Valeant Pharmaceuticals International in a research report on Thursday, August 11th. Finally, Royal Bank Of Canada lifted their price objective on Valeant Pharmaceuticals International from $31.00 to $36.00 and gave the company a “sector perform” rating in a research report on Wednesday, August 10th. Four analysts have rated the stock with a sell rating, fifteen have issued a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $40.18.

Analyst Recommendations for Valeant Pharmaceuticals International (NYSE:VRX)

Valeant Pharmaceuticals International (NYSE:VRX) opened at 16.82 on Wednesday. Valeant Pharmaceuticals International has a 12 month low of $13.77 and a 12 month high of $119.87. The firm’s 50-day moving average is $22.29 and its 200-day moving average is $25.33. The company’s market capitalization is $5.85 billion.

Valeant Pharmaceuticals International (NYSE:VRX) last announced its earnings results on Tuesday, November 8th. The specialty pharmaceutical company reported $1.55 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.78 by $0.23. The firm earned $2.48 billion during the quarter, compared to analysts’ expectations of $2.49 billion. Valeant Pharmaceuticals International had a positive return on equity of 41.02% and a negative net margin of 22.17%. The company’s revenue for the quarter was down 11.0% on a year-over-year basis. During the same period in the previous year, the business posted $2.74 earnings per share. Equities analysts anticipate that Valeant Pharmaceuticals International will post $6.45 EPS for the current fiscal year.

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Morgan Stanley raised its position in shares of Valeant Pharmaceuticals International by 241.6% in the third quarter. Morgan Stanley now owns 5,967,745 shares of the specialty pharmaceutical company’s stock valued at $146,508,000 after buying an additional 4,220,573 shares in the last quarter. Acrospire Investment Management LLC raised its position in shares of Valeant Pharmaceuticals International by 300.0% in the third quarter. Acrospire Investment Management LLC now owns 13,200 shares of the specialty pharmaceutical company’s stock valued at $324,000 after buying an additional 9,900 shares in the last quarter. Northern Trust Corp raised its position in shares of Valeant Pharmaceuticals International by 24.3% in the third quarter. Northern Trust Corp now owns 282,495 shares of the specialty pharmaceutical company’s stock valued at $6,935,000 after buying an additional 55,209 shares in the last quarter. Columbus Circle Investors raised its position in shares of Valeant Pharmaceuticals International by 24.6% in the third quarter. Columbus Circle Investors now owns 155,280 shares of the specialty pharmaceutical company’s stock valued at $3,812,000 after buying an additional 30,662 shares in the last quarter. Finally, Princeton Alpha Management LP acquired a new position in shares of Valeant Pharmaceuticals International during the third quarter valued at about $361,000. 64.39% of the stock is currently owned by institutional investors.

Valeant Pharmaceuticals International Company Profile

Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).

5 Day Chart for NYSE:VRX

Receive News & Stock Ratings for Valeant Pharmaceuticals International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals International Inc. and related stocks with our FREE daily email newsletter.